Phase 1 studies of trebananib (AMG 386; first Ang-1 and Ang-2 blocker) also showed acceptable toxicity profile in patients with solid tumours.5,19,20 Fatigue, abdominal pain and peripheral oedema were the main TEAEs,5 as with LY3127804. Here, ANGPT2 is linked to Peripheral edema.